Cebpa, also known as CCAAT enhancer binding protein α, is a key transcription factor involved in the regulation of gene expression. It plays a crucial role in processes such as granulocyte differentiation and hematopoiesis, and is associated with pathways related to cell development and function in the hematopoietic system [2,3,5,6]. Genetic models, like KO/CKO mouse models, are valuable for studying its functions.

In acute myeloid leukemia (AML), Cebpa mutations have significant prognostic implications. Biallelic Cebpa mutations are associated with favorable outcomes, and in-frame mutations in the basic leucine zipper domain (CEBPAbZIP-inf) confer a survival benefit [1,2,3,4,5]. Co-occurring mutations can also impact prognosis; for example, co-occurring CSF3R and Cebpa mutations are associated with a high relapse rate, nullifying the favorable prognostic impact of Cebpa mutations [1]. Different types of Cebpa mutations, such as those in the bZIP domain or transcription activation domain (TAD), have differential impacts on patient outcomes, with bZIP domain in-frame mutations being associated with improved survival [3,4,5].

In conclusion, Cebpa is essential for normal hematopoietic processes, especially granulocyte differentiation. In the context of AML, research using genetic models has revealed that specific Cebpa mutations, particularly in-frame bZIP domain mutations, are associated with a favorable prognosis, highlighting the importance of understanding Cebpa mutations for risk stratification and treatment in AML [1,2,3,4,5,6].

References:

1. Tarlock, Katherine, Lamble, Adam J, Wang, Yi-Cheng, Alonzo, Todd A, Meshinchi, Soheil. . CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. In Blood, 138, 1137-1147. doi:10.1182/blood.2020009652. https://pubmed.ncbi.nlm.nih.gov/33951732/

2. Tien, Feng-Ming, Hou, Hsin-An. 2024. CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment. In International journal of hematology, 120, 541-547. doi:10.1007/s12185-024-03773-5. https://pubmed.ncbi.nlm.nih.gov/38671183/

3. Taube, Franziska, Georgi, Julia Annabell, Kramer, Michael, Schetelig, Johannes, Thiede, Christian. . CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. In Blood, 139, 87-103. doi:10.1182/blood.2020009680. https://pubmed.ncbi.nlm.nih.gov/34320176/

4. Georgi, Julia-Annabell, Stasik, Sebastian, Kramer, Michael, Gale, Rosemary, Thiede, Christian. 2024. Prognostic impact of CEBPA mutational subgroups in adult AML. In Leukemia, 38, 281-290. doi:10.1038/s41375-024-02140-x. https://pubmed.ncbi.nlm.nih.gov/38228680/

5. Wakita, Satoshi, Sakaguchi, Masahiro, Oh, Iekuni, Inokuchi, Koiti, Yamaguchi, Hiroki. . Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. In Blood advances, 6, 238-247. doi:10.1182/bloodadvances.2021004292. https://pubmed.ncbi.nlm.nih.gov/34448807/

6. Yuan, Ji, He, Rong, Alkhateeb, Hassan B. 2023. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations. In Current hematologic malignancy reports, 18, 121-129. doi:10.1007/s11899-023-00699-3. https://pubmed.ncbi.nlm.nih.gov/37261703/